Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients by MD et al.
Effects of sufentanil or ketamine administered in target-controlled
infusion on the cerebral hemodynamics of severely brain-injured
patients*
Aurélie Bourgoin, MD; Jacques Albanèse, MD; Marc Léone, MD; Emmanuelle Sampol-Manos, PhD;
Xavier Viviand, MD; Claude Martin, MD, FCCM
An important objective in themanagement of severely brain-injured patients is the mainte-nance of a cerebral perfusion
pressure of 60 mm Hg. The aim of
sedation is to prevent intracranial hyper-
tension due to pain or agitation. Before
noxious stimuli, such as endotracheal
suction, brain-injured patients require
more analgesic drug to avoid transient
intracranial hypertension. However, the
manual administration of a bolus of opioids
has been associated with a significant in-
crease in intracranial pressure (ICP) related
to a decrease in blood pressure in severely
brain-injured patients under mechanical
ventilation (1). Ketamine is not commonly
used in severely brain-injured patients.
Nevertheless, two studies show that ket-
amine in combination with midazolam or
propofol does not affect and even may de-
crease ICP at higher doses in mechanically
ventilated patients with decreased intracra-
nial compliance following severe head
trauma (2–4). A manual bolus of ketamine
administered to the same patients has no
deleterious effect on ICP and blood pres-
sure (4). The use of target-controlled infu-
sion (TCI) makes it possible to maintain a
better degree of hemodynamic stability
compared with manual administration dur-
ing anesthesia (5). However, the use of TCI
to provide sedation in traumatic brain-
injured patients has never been investi-
gated. One could expect to obtain an in-
crease in plasma concentrations of
analgesic drugs without deleterious cere-
bral hemodynamic effects for sufentanil.
We used ketamine as a comparator.
The aim of this study was to compare
the effects of an increase in plasma con-
centrations of sufentanil and ketamine,
administered by TCI, on cerebral hemo-
dynamics.
MATERIALS AND METHODS
Group Assignment. After approval by the
Ethics Committee of our institution, we ob-
tained informed consent from each patient’s
next of kin. Thirty patients with severe head
injury were enrolled in the study after initial
resuscitation. Inclusion criteria were as fol-
lows: severe traumatic brain injury resulting
in a postresuscitation Glasgow Coma Scale
score 9, analysis of the first computed to-
mography scan according to the Traumatic
Coma Data Bank 2 (6), ICP monitoring re-
quired, and age 18–75 yrs. Patients were ran-
domized to receive sedation with sufentanil
*See also p. 1172.
From the Department of Anesthesiology and Inten-
sive Care and Trauma Center, Nord Hospital (AB, JA,
ML, XV, CM) and the Department of Pharmacokinetics,
Timone Hospital (ES-M), Marseille University Hospital
System, France.
Supported, in part, by a grant from the Direction de
la Recherche et de l’Innovation-Assistance Publique
Marseille (PHRC 1997).
Copyright © 2005 by the Society of Critical Care
Medicine and Lippincott Williams & Wilkins
DOI: 10.1097/01.CCM.0000162491.26292.98
Objective: The manual injection of a bolus of opioid in patients
with brain injury induces an increase in intracranial pressure related
to a decrease in mean arterial pressure. Such an effect has not been
observed with the use of ketamine. The use of target-controlled
infusion would minimize or suppress this adverse effect of opioid.
This study evaluated the effects of an increase in plasma concen-
trations of sufentanil or ketamine administered by target-controlled
infusion on cerebral hemodynamics.
Design: Prospective, randomized study.
Setting: Intensive care unit in a trauma center.
Patients: Thirty patients with severe traumatic brain injury.
Interventions: Patients were assigned to receive sedation con-
sisting of sufentanil-midazolam or ketamine-midazolam using
target-controlled infusion. Twenty-four hours after the onset of
sedation, the target concentrations of sufentanil or ketamine were
doubled for 15 mins. Blood samples were collected to determine
the actual plasma concentration of sufentanil and ketamine,
before and 15 mins after concentration change.
Measurements and Main Results: The baseline values of in-
tracranial pressure and cerebral perfusion pressure were similar
in both groups. The two-fold increase in drug concentrations did
not involve a significant change for intracranial pressure, cerebral
perfusion pressure, and mean velocity of middle cerebral artery in
both the ketamine and the sufentanil groups. The measured
plasma concentrations of sufentanil and ketamine were 0.4  0.2
ng/mL and 2.6  2.2 g/mL, respectively, before the increase in
concentrations and 0.7  0.4 ng/mL and 5.5  3.8 g/mL after.
Conclusions: The present study shows that the increase in
sufentanil or ketamine plasma concentrations using a target-
controlled infusion is not associated with adverse effects on
cerebral hemodynamics in patients with severe brain injury. The
use of target-controlled infusion could be of interest in the man-
agement of severely brain-injured patients. However, there is a
need for specific pharmacokinetic models designed for intensive
care unit patients. (Crit Care Med 2005; 33:1109–1113)
KEY WORDS: severe head injury management; target-controlled
infusion; ketamine; sufentanil; intensive care unit; intracranial
pressure; cerebral perfusion pressure
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and midazolam in the sufentanil group or with
ketamine and midazolam in the ketamine
group according to a randomization table.
Both drugs were administered by TCI using
PaMo software (7). A syringe pump (Pilote C,
Fresenius, Grenoble, France) was driven by a
personal computer.
Patient Management. TCI was initiated
when intracranial monitoring was required.
TCI was initiated with a target plasma concen-
tration of 0.3 ng/mL sufentanil and 100 ng/mL
midazolam in the sufentanil group and of 1.0
g/mL ketamine and 100 ng/mL midazolam
in the ketamine group. Efficacy of sedation
was evaluated on obtaining five criteria based
on a behavioral pain scale (8) reported in Table
1. Next, predictive plasma concentrations were
adjusted step by step (0.15 ng/mL for sufen-
tanil or 0.5 g/mL for ketamine and 50 ng/mL
for midazolam) to reach these criteria.
Arterial pressure in CO2 was maintained
between 35 and 38 mm Hg. Management was
in agreement with the previously published
guidelines for managing patients with severe
head injury (9).
Monitoring. Mean arterial pressure (MAP)
was continuously monitored via an arterial
catheter. Intracranial pressure measurements
were obtained through a frontal ventricular
catheter system with a Camino transducer
(Camino V420 monitor, Camino Laboratories,
San Diego, CA). From these last two variables,
cerebral perfusion pressure (CPP  MAP 
ICP) was continuously calculated and dis-
played on the monitor. Zero level was checked
before use of each Camino transducer. A
2-MHz pulsed Doppler ultrasound device (An-
giodine 2; DMS, Montpellier, France) was used
to measure erythrocyte velocity. After identi-
fication of the right anterior cerebral artery
and middle cerebral artery, the depth was ad-
justed by 2-mm increments to obtain signals
from the proximal (M1) segment of the middle
cerebral artery. The electroencephalogram
was recorded continuously using an Aspect
A-1000 electroencephalogram monitor (As-
pect Medical Systems, version 3.12), which
also computed the bispectral index (BIS) in
real time. Silver/silver chloride pre-gelled
electrodes (3M Red Dot 2360, Pithiviers,
France) were applied to the left and right
frontal (Fp1 and Fp2) regions and referred to a
vertex electrode (CZ). Electrode impedance
was maintained 5 k.
Protocol. The experimental protocol is pre-
sented in Figure 1. Twenty-four hours after
the onset of sedation, the target plasma con-
centrations of sufentanil or ketamine were
doubled. Target plasma concentrations of mi-
dazolam were unchanged during the entire
protocol. Since requirements in sedation dif-
fer for individual patients, we chose to per-
form a two-fold increase in sufentanil or ket-
amine plasma concentrations to standardize
the effects on cerebral hemodynamics.
The effects of this increase in concentra-
tions were serially evaluated on systemic
(MAP) and cerebral hemodynamics by mea-
surements of ICP, CPP, and mean velocity of
middle cerebral artery (VMCAM). All variables
were measured every minute for 5 mins before
and every minute for 15 mins after drug con-
centration increase. Changes in BIS were
monitored during the protocol. For both
groups, the variables that could have affected
ICP and CPP were recorded: arterial hemoglo-
bin oxygen saturation, end-tidal fraction in
CO2, and body temperature. We noted require-
ments in fluid replacement or vasopressor for
maintaining blood pressure.
Pharmacokinetics and Dosages. The phar-
macokinetics used in TCI were from Domino et
al. (10) for ketamine, Hudson et al. (11) for
sufentanil, and Avram et al. (12) for midazolam.
Two arterial blood samples were obtained
to assess ketamine, sufentanil, and midazolam
plasma concentrations: one 5 mins before and
one 15 mins after concentration change. The
concentrations of ketamine (13) and midazo-
lam (14) were analyzed by a previously de-
scribed high-performance liquid chromatog-
raphy method and those of sufentanil by
radioimmunoassay (15).
Statistics. Data are presented as mean 
SD. Baseline values represent an average of five
measurements obtained during a 5-min period
before concentrations increase. For patient
characteristics, qualitative data were com-
pared using a chi-square test, and quantitative
data were compared with the Student’s t-test
for unpaired data. Physiologic measures were
analyzed with a repeated-measures analysis of
variance and the Newman-Keuls’ test. We con-
sidered p  .05 as significant.
RESULTS
Patient characteristics including age,
postresuscitation Glasgow Coma Scale
score, Injury Severity Score, analysis of first
tomography scan according to the Trau-
matic Coma Data Bank, and cerebral inju-
ries are reported in Table 2. Two patients in
each group underwent neurosurgery to
evacuate a hematoma before protocol: one
subdural and one extradural hematoma in
the sufentanil group and one subdural with
decompressive craniectomy and one intra-
cerebral hematoma in the ketamine group.
Three patients underwent other surgery
(abdominal, orthopedics) before protocol,
in each group. One patient had hemor-
rhagic shock in each group.
TCI was initiated 32  19 hrs in the
sufentanil group and 30  25 hrs in the
ketamine group after the trauma.
The baseline values for arterial hemo-
globin oxygen saturation, end-tidal frac-
tion in CO2, and body temperature were
similar in the two groups (Table 2). No
significant changes occurred during the
experiment.
Figure 1. Experimental protocol. Sedation with target-controlled infusion was initiated when intra-
cranial pressure monitoring was required. Plasma concentrations of sufentanil, ketamine, and mida-
zolam were adjusted during 24 hrs according to clinical criteria. Then sufentanil or ketamine plasma
concentrations were increased two-fold.
Table 1. Sedation levels were adjusted to obtain five criteria
Absence of agitation
No fighting with ventilator
Relaxed facial expression
Absence of neurovegetative troublesa
Absence of intracranial hypertension related to nonnociceptive stimulationsb
aTachycardia, hyperventilation, hypertension; bexternal noises, lights on/off, interventions on
intravascular catheters.
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Effect on Hemodynamics. The base-
line value of ICP was 17.7  6.5 mm Hg
(9–30 mm Hg) in the sufentanil group
compared with 16.2  6.4 mm Hg (9–28
mm Hg) in the ketamine group (not sig-
nificant). The baseline value of CPP was
not significantly different between the
sufentanil and ketamine groups (80  14
mm Hg vs. 85  14 mm Hg, not signif-
icant). The two-fold increase in sufentanil
or ketamine concentrations did not in-
volve significant changes in MAP, ICP,
and CPP compared with the baseline val-
ues (Fig. 2). No significant difference was
observed between the two groups. No pa-
tient received vasopressor or fluid re-
placement during the experiment.
The baseline value of VMCAM was sig-
nificantly higher in the sufentanil group
than in the ketamine group (77  21
cm/sec vs. 60  33 cm/sec, p  .03).
However, no significant change was re-
lated to the two-fold increase in drug
concentrations (Fig. 3a). The baseline
value of BIS was not significantly differ-
ent in the ketamine group compared with
that of the sufentanil group (74  20%
vs. 65  25%, p  .29). A significant
difference occurred 6, 7, and 13 mins
after the two-fold increase in drug plasma
concentrations (p  .05, Fig. 3b).
Plasma Concentrations. At the onset
of the experiment, predictive plasma con-
centrations of sufentanil and midazolam
were 0.4  0.1 ng/mL and 158  75
ng/mL, respectively, for the sufentanil
group. Predictive plasma concentrations
of ketamine and midazolam were 1.6 
0.8 g/mL and 138  60 ng/mL, respec-
tively, for the ketamine group. At these
plasma concentrations, the five criteria of
efficacy of sedation were obtained for all
patients. Measured plasma concentra-
tions are represented in Table 3. The ratio
(concentration after increase/concentra-
tion before increase) was 1.8  0.3 for
sufentanil and 2.5  1.9 for ketamine—
this difference was not significant (p 
.23). Measured plasma concentrations of
midazolam remained unchanged in both
groups during the protocol, with no sig-
nificant difference.
DISCUSSION
The present study investigated the ef-
fects of sufentanil or ketamine adminis-
tered through a TCI system in patients
with severe traumatic brain injury. To
our knowledge, this is the first study in-
vestigating the use of TCI for sedation in
such intensive care unit (ICU) patients. A
two-fold increase in sufentanil or ket-
amine plasma concentrations adminis-
tered by TCI did not induce a deleterious
effect on cerebral hemodynamics.
The increase in ICP after a manual
bolus of opioids is mostly related to a
decrease in MAP, probably due to an ac-
tivation of the vasodilatory cascade (1,
16). The possibility with the TCI system
to administer opioids slowly with a sig-
nificant decrease in cumulative dose
should make it possible to achieve a bet-
ter hemodynamic stability (5, 17). The
infusion rates, which are controlled by
software, depend on the duration of infu-
sion, the pharmacokinetic properties of
each drug, and patient characteristics. To
apply our protocol manually, we calcu-
lated for each group the infusion rate of
drugs required to achieve the same ob-
jective: the infusion rates were 95 g/kg/
min ketamine and 1.5 g/kg/min mida-
Figure 2. Mean values of intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean
arterial pressure (MAP) after ketamine (K) and sufentanil (S) plasma concentration two-fold increase.
Table 2. Patient population
Sufentanil (n  15) Ketamine (n  15)
Age, yrs, mean  SD 29  12 29  11
Weight, kg, mean  SD 75  9 71  18
Postresuscitation Glasgow Coma Scale, median 6 5
Traumatic Coma Data Bank, median 3 2
Injury Severity Score, median 32 29
Cerebral injuries
Multiple contusions 9 10
Subdural hematoma 4 2
Extradural hematoma 2 1
Intraventricular hemorrhage 2 2
Subarachnoid hemorrhage 2 1
Severe edema 3 3
Body temperature, °C, mean  SD 37.2  0.9 37.1  0.9
SaO2, %, mean  SD 99  0.8 98  1.3
FetCO2, mm Hg, mean  SD 28.4  5 28.7  4.3
SaO2, arterial hemoglobin oxygen saturation; FetCO2, end-tidal fraction in CO2.
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zolam in the ketamine group and 0.007
g/kg/min sufentanil and 1.7 g/kg/min
midazolam in the sufentanil group. We
found similar requirement in a previous
study (2). The mean doses of ketamine or
sufentanil that were administered to
achieve a plasma concentration two-fold
increase were 180 mg and 15 g, respec-
tively. Concerning sufentanil, this slow
infusion rate could probably explain the
discordance with previous studies (1) that
showed a decrease in CPP related to opi-
oid bolus administration. Actually, rapid
injection of sedative agents produces sig-
nificantly higher peak arterial concentra-
tions, inducing a systemic effect (18). As
opposed to bolus, a continuous infusion
of sufentanil did not alter MAP and ICP
(1). Werner et al. (19) emphasized the
role of MAP, showing that a bolus of
sufentanil did not change ICP when MAP
was maintained constant by the use of a
norepinephrine infusion.
Drug administration by TCI is not cur-
rently used in clinical practice for ICU
patients. Most of the available models
have been studied in patients undergoing
surgery. There are actually few pharma-
cokinetic models for sedative drugs
adapted to ICU patients. Significant dif-
ferences in pharmacokinetic data have
been observed between ICU patients and
healthy volunteers; for instance, in-
creased distribution volume, protein
binding reduction, and drug clearance
disturbances are frequent in ICU patients
(20). To verify the accuracy of the plasma
concentration two-fold increase, we col-
lected blood and measured the concen-
trations of each agent. The prediction of
the model was accurate for sufentanil but
not for ketamine and midazolam. The
performance of these last models was not
designed for our population of mechani-
cally ventilated ICU patients. Neverthe-
less, the two-fold increase in plasma
concentrations that was predicted for
the experiment was confirmed by the
measured plasma concentrations for
both sufentanil and ketamine.
According to the literature, ketamine
and sufentanil have different effects on
cerebral hemodynamics. The cerebrovas-
cular effects of ketamine remain contro-
versial. This drug is not commonly used
in clinical practice for the sedation of
brain-injured patients. Indeed, the cere-
brovascular effects of ketamine depend
on the preexisting cerebrovascular tone
induced by the background anesthetic
(21) and by other factors influencing ce-
rebral hemodynamics such as PaCO2 and
MAP levels. However, in several studies,
the use of ketamine has been shown to be
safe and effective in head-injured patients
(2–4). Continuous infusion of ketamine-
midazolam was as efficient as sufentanil-
midazolam on ICP and CPP control in
patients with severe head injury (2). Ko-
lenda et al. (3) compared the effects of a
continuous infusion of ketamine-midazo-
lam with those of fentanyl-midazolam on
ICP and CPP and reported similar results.
A bolus of ketamine decreased or did not
change ICP and CPP in mechanically ven-
tilated head-trauma patients sedated with
propofol (4). All these studies were car-
ried out in mechanically ventilated pa-
tients to maintain a PaCO2 of approxi-
mately 35 mm Hg, and ketamine was
used in combination with midazolam or
propofol. The use of midazolam or propo-
fol could limit the effects of ketamine on
cerebral blood flow (21, 22). However,
ketamine has an interesting profile for
sedation of severely brain-injured pa-
tients, especially in case of instable he-
modynamic state.
The baseline VMCAM values were signif-
icantly different in the two groups. We do
not have a clear explanation for this obser-
vation since such a finding was not ob-
served in our previous study (2). Midazolam
induced dose-related changes in cerebral
blood flow, but the difference in measured
plasma concentrations of midazolam was
not significant between the ketamine and
sufentanil groups (232  149 and 284 
246 ng/mL, respectively) (23). Nevertheless
the two-fold increase in ketamine or sufen-
tanil concentrations did not induce signif-
icant changes in VMCAM.
The reliability of monitoring sedation
by BIS is not known in patients with
traumatic brain injury. In the present
study, BIS was measured to assess a dif-
ference between the two groups related to
the analgesic drug. In the present study,
Figure 3. Mean values of mean velocity of middle cerebral artery (VMCAM) and bispectral index (BIS)
after ketamine (K) and sufentanil (S) plasma concentration two-fold increase. *p  .05.
Table 3. Measured and predictive plasma concentrations of the sedative drugs: one dosage 5 mins
before and one dosage 15 mins after drug concentration two-fold increase









Sufentanil, ng/mL; ketamine, g/mL
Measured concentrations 0.4  0.2 0.7  0.3 2.6  2.2 5.5  3.8
Predictive concentrations 0.4  0.1 0.8  0.2 1.6  0.8 3.2  1.6
Midazolam, ng/mL
Measured concentrations 284  246 278  241 232  149 228  143
Predictive concentrations 158  75 158  75 138  60 138  60
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the BIS values were higher in the ket-
amine group. Such a finding is in agree-
ment with those of previous studies in
which the administration of ketamine did
not affect BIS (24–26). In healthy volun-
teers, low to moderate doses of opioids do
not change the BIS (27), but in patients
with traumatic brain injury, high doses of
remifentanil induce a dose-related de-
crease in the BIS (28). Nevertheless, BIS
is not really suited to monitor sedation in
ICU patients. Vivien et al. (29) showed
that BIS was overestimated in ICU pa-
tients receiving sedation.
The clinical utility of TCI in severely
brain-injured patients would be to decrease
sedation level during nonnociceptive stim-
ulation and increase sedation level before
nociceptive stimulation without side effects
on ICP and CPP meeting with manual bo-
lus injection. In this study, we observed no
side effects on ICP and CPP related to a
sufentanil or ketamine plasma concentra-
tion two-fold increase by TCI. The next step
will be to evaluate in further studies the
effects on a noxious stimulation, such as
endotracheal suction.
CONCLUSIONS
This prospective randomized study
shows that a sufentanil or ketamine
plasma concentration two-fold increase
by TCI was not followed by any changes
in ICP and CPP in patients with trau-
matic brain injury. This is the first study to
evaluate the use of TCI in severely brain-
injured patients. The administration of an
opioid bolus through a TCI perfusion sys-
tem could be of interest since this system
makes it possible to reduce the systemic
effects of opioids and to minimize their
detrimental impact on cerebral hemody-
namics. However, the extensive use of TCI
in ICU patients is required to conceive spe-
cific pharmacokinetic models adapted to
this specific population.
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